Generation Bio Co. (NASDAQ:GBIO) – Research analysts at Wedbush issued their Q2 2020 earnings per share (EPS) estimates for shares of Generation Bio in a research report issued on Tuesday, July 7th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.33) per share for the quarter. Wedbush currently has a “Outperform” rating and a $31.00 price objective on the stock. Wedbush also issued estimates for Generation Bio’s Q3 2020 earnings at ($0.41) EPS, Q4 2020 earnings at ($0.53) EPS, FY2020 earnings at ($1.76) EPS, FY2021 earnings at ($2.22) EPS, FY2022 earnings at ($1.70) EPS, FY2023 earnings at ($2.08) EPS and FY2024 earnings at ($2.46) EPS.

Other research analysts have also issued research reports about the stock. Jefferies Financial Group started coverage on shares of Generation Bio in a report on Tuesday. They issued a “buy” rating and a $38.00 price objective for the company. Cowen started coverage on shares of Generation Bio in a report on Tuesday. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Generation Bio in a report on Tuesday. They issued an “overweight” rating and a $28.00 price objective for the company.

Shares of NASDAQ GBIO opened at $19.71 on Thursday. Generation Bio has a 1 year low of $18.51 and a 1 year high of $24.90.

In other news, insider James E. Flynn purchased 225,000 shares of the stock in a transaction on Tuesday, June 16th. The stock was purchased at an average price of $19.00 per share, for a total transaction of $4,275,000.00.

About Generation Bio

Generation Bio Co develops gene therapies for the treatment of genetic diseases. It focuses in the areas of liver, eye, muscle, and brain disorders. Generation Bio Co was formerly known as Torus Therapeutics, Inc and changed its name to Generation Bio Co in November 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.

Read More: Analyzing a company’s cash flow statement

Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.